Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT01156870 | First in Man Study of SAR566658 Administered in Patients With CA6-Positive and Refractory Solid Tumor | PHASE1 | COMPLETED | 114 | — | — | Sep 8, 2010 | Apr 7, 2017 | May 10, 2017 | 5 | United States, France +1 |
| Arm | Type | Description |
|---|---|---|
| SAR566658 | EXPERIMENTAL | SAR566658 will be administered by intravenous (IV) infusion according to three different schedules |
| Name | Type | Description |
|---|---|---|
| SAR566658 | DRUG | Pharmaceutical form:solution for infusion Route of administration: intravenous |
Inclusion criteria: Diagnosis of CA6-positive solid tumors as moderate to intense membrane staining of ≥15% of tumor cells for which no standard therapy is available. Exclusion criteria: * Eastem Cooperative Oncology Group performance status ≥2. * Any serious active disease or co-morbid condition...